{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:23Z","timestamp":1785473963960,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Diffuse large B-cell lymphoma (DLBCL) is characterized by marked clinical heterogeneity, and conventional prognostic indices provide limited individualized risk prediction. We investigated the prognostic value of baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT-derived volumetric metabolic parameters in newly diagnosed DLBCL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 176 consecutive patients with histologically confirmed DLBCL who underwent baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT before first-line R-CHOP or R-CHOP-like immunochemotherapy between January 2022 and December 2024. Metabolic tumor volume (MTV) was measured using a 41% SUVmax threshold, and total lesion glycolysis (TLG) was calculated as MTV \u00d7 SUVmean. Optimal cutoff values were determined by ROC analysis. Survival outcomes were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Predictive performance was assessed by Harrell\u2019s C-index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 58 years, and 54.5% of patients were male. After a median follow-up of 26.4 months, 48 patients experienced progression; including 5 deaths without documented progression, the composite progression-free survival (PFS) endpoint comprised 53 events, and 30 patients died. The optimal cutoffs were 274.8 cm\u00b3 for MTV and 1,886.3 g for TLG. High MTV was associated with significantly inferior 2-year PFS (50.7% vs 79.9%; P&amp;lt;0.001) and OS (71.3% vs 92.8%; P&amp;lt;0.001). In multivariable analysis, high MTV remained the only significant independent predictor of PFS (HR 3.16, 95% CI 1.82-5.50; P&amp;lt;0.001). Incorporating MTV into the IPI improved discrimination compared with IPI alone (C-index 0.697 vs 0.567).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center cohort, baseline MTV was a robust independent prognostic biomarker for PFS that substantially enhanced risk stratification beyond the IPI; its association with OS was exploratory given the limited number of events. Integration of volumetric PET\/CT metrics into prognostic models may facilitate more individualized therapeutic decision-making. The optimism-prone, internally derived cutoff requires external validation; prospective, multicenter validation with standardized measurement protocols is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1862170","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:08Z","timestamp":1785471908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic tumor volume and total lesion glycolysis for predicting prognosis in diffuse large B-cell lymphoma: a retrospective PET\/CT study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"You","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Henan Provincial People\u2019s Hospital\/People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henan Provincial People\u2019s Hospital\/People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Zhen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henan Provincial People\u2019s Hospital\/People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henan Provincial People\u2019s Hospital\/People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henan Provincial People\u2019s Hospital\/People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020779","article-title":"DLBCL: who is high risk and how should treatment be optimized","volume":"144","author":"Dabrowska-Iwanicka","year":"2024","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40487-024-00265-8","article-title":"Epidemiology and real-world treatment of incident diffuse large B-cell lymphoma (DLBCL): a German claims data analysis","volume":"12","author":"Pacis","year":"2024","journal-title":"Oncol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02775-9","article-title":"Treatment outcomes with standard of care in relapsed\/refractory diffuse large B-cell lymphoma: real-world data analysis","volume":"41","author":"Ip","year":"2024","journal-title":"Adv Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27075","article-title":"2024 update: advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli","year":"2023","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104293","article-title":"Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review","volume":"196","author":"Jelicic","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-025-00623-z","article-title":"Prognostic outcomes of diffuse large B-cell lymphoma patients with myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) co-expression","volume":"18","author":"Kumjan","year":"2025","journal-title":"J Hematopathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/MNM.0000000000001664","article-title":"Prognostic parameters on baseline and interim [18F]FDG-PET\/computed tomography in diffuse large B-cell lymphoma patients","volume":"44","author":"Czibor","year":"2023","journal-title":"Nucl Med Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05717-9","article-title":"Metabolic tumor volume from baseline [18F]FDG PET\/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma","volume":"103","author":"Zhang","year":"2024","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1561","article-title":"PET\/CT biomarkers enable risk stratification of patients with relapsed\/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial","volume":"30","author":"Alderuccio","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.121","article-title":"Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial","volume":"35","author":"Cottereau","year":"2024","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268152","article-title":"International Metabolic Prognostic Index is superior to other metabolic tumor volume-based prognostication methods in a real-life cohort of diffuse large B-cell lymphoma","volume":"65","author":"Vergote","year":"2024","journal-title":"J Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.994520","article-title":"Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers","volume":"14","author":"Choi","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267789","article-title":"International benchmark for total metabolic tumor volume measurement in baseline 18F-FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation","volume":"65","author":"Boellaard","year":"2024","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012165","article-title":"Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study","volume":"8","author":"Ikeda","year":"2024","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06686-3","article-title":"Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk","volume":"104","author":"Duminuco","year":"2025","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1395824","article-title":"Baseline and interim 18F-FDG PET\/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma","volume":"14","author":"Liao","year":"2024","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","article-title":"Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models","volume":"13","author":"Jelicic","year":"2023","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287241","article-title":"Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response","volume":"110","author":"Eertink","year":"2025","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s40644-024-00810-8","article-title":"Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET\/CT image analysis for prognosis of diffuse large B-cell lymphoma","volume":"24","author":"Sun","year":"2024","journal-title":"Cancer Imaging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16377","article-title":"The prognostic significance of MYC\/BCL2 double expression in DLBCL in the genetic classification era","volume":"116","author":"Wu","year":"2025","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19458","article-title":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","volume":"205","author":"Alcoceba","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:09Z","timestamp":1785471909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1862170"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1862170","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1862170"}}